<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00168220</url>
  </required_header>
  <id_info>
    <org_study_id>113/05</org_study_id>
    <nct_id>NCT00168220</nct_id>
  </id_info>
  <brief_title>Predictors of Drug Hypersensitivity in HIV Infected Subjects</brief_title>
  <official_title>Predictors of Drug Hypersensitivity in HIV Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Alfred</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Alfred</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A case-control study to look at hypersensitive and tolerant individuals matched for HLA
      genetic predisposition, when considering predictors of drug hypersensitivity.The study aims
      to identify the immunological factors increasing the risk of drug reactions in HIV positive
      individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To determine in a case control study clinical parameters associated with drug HSR to
           abacavir, nevirapine and efavirenz in HIV infected subjects.

        2. To measure functional and numerical differences in DC populations and responses to TLR
           ligands in patients with HSR and tolerant subjects sharing genetic markers for
           susceptibility to HSR.

        3. Identify the role of different DC populations in the development of abacavir reaction by
           mixing and depletion studies in sensitized subjects and in in vitro assays for abacavir
           hypersensitivity.

        4. To measure T cell parameters including T cell viability in culture, and expression of
           fas and fasL on blood mononuclear cells in HIV infected controls and HSR patients.

        5. To measure blood T cell populations including drug reactive T cells and T regulatory
           cells in tolerant and reactive subjects with genetic susceptibility to Abacavir and
           Nevirapine HSR.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Insufficient recruitment
  </why_stopped>
  <start_date>August 2005</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>HIV Infections</condition>
  <condition>Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>Drug hypersensitive group</arm_group_label>
    <description>HIV positive patients with a history of a Hypersensitivity Reaction to the antiretroviral medications Nevirapine, Abacavir or Efavirenz</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug tolerant group</arm_group_label>
    <description>HIV positive patients selected based on drug exposure greater than 2 weeks and tolerance to to Abacavir or Nevirapine.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV infection, exposed to antiretroviral treatment, either tolerant or hypersensitive to
        treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infected patients on treatment with the drugs Efavirenz, Nevirapine, or Abacavir.

          -  Age over 18 Cases are those who have had a hypersensitivity reaction, and controls are
             those who have had no reaction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Cameron, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Alfred</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>January 19, 2012</last_update_submitted>
  <last_update_submitted_qc>January 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Alfred</investigator_affiliation>
    <investigator_full_name>Jennifer Hoy</investigator_full_name>
    <investigator_title>Professor Jennifer Hoy</investigator_title>
  </responsible_party>
  <keyword>Treatment Experienced</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Drug Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

